Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics reported strong financial results for Q4 and full-year 2020, with net product sales reaching $122.6 million and $455.9 million, respectively. This marks a 23% increase in Q4 sales compared to 2019 and a nearly 20% increase for the year. A key highlight is the FDA approval of AMONDYS 45 for Duchenne muscular dystrophy, enhancing treatment options for 8% of patients with specific mutations. The firm is advancing its pipeline with significant developments in gene therapy and RNA platforms, aiming to address over 80% of Duchenne mutations.

Sarepta Therapeutics (NASDAQ:SRPT) announced the grant of equity awards to two new employees on February 26, 2021, as per the Compensation Committee's approval. The awards include options for 1,820 shares of common stock at an exercise price of $87.06, equal to the closing price on the grant date, and 680 restricted stock units. Vesting is set to occur over four years, contingent upon continued employment. Sarepta focuses on precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy and gene therapies.

Sarepta Therapeutics (NASDAQ: SRPT) has received FDA approval for AMONDYS 45 (casimersen), its third RNA exon-skipping treatment for Duchenne muscular dystrophy (DMD), specifically for patients with exon 45 amenable mutations. This approval is based on statistically significant increases in dystrophin production in treated patients. Commercial distribution will start immediately, with ongoing confirmatory trials expected to conclude in 2024. The treatment carries a potential risk of kidney toxicity, necessitating close monitoring of kidney function.

Sarepta Therapeutics, a leader in precision genetic medicine, announced participation in two upcoming virtual investor conferences. Management will speak at the Cowen 41st Annual Health Care Conference on Mar. 3, 2021, at 2:40 p.m. E.T., and at the Barclays Global Healthcare Conference on Mar. 10, 2021, at 2:25 p.m. E.T.. Both presentations will be available via live webcasts on Sarepta's website and archived for 90 days. The company focuses on genetic treatments for rare diseases, including Duchenne muscular dystrophy, with over 40 development programs.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will disclose its fourth quarter and full-year 2020 financial results on March 1, 2021, after the Nasdaq closes. A conference call will follow at 4:30 p.m. E.T. to discuss the results and provide a corporate update. Investors can access the call at (844) 534-7313 for domestic or (574) 990-1451 for international, using passcode 9672289. Sarepta specializes in precision genetic medicine, particularly in DMD and gene therapies for various rare diseases, with over 40 programs in development.

Sarepta Therapeutics (NASDAQ:SRPT) announced the winners of its Rare Lessons lesson planning competition, awarding each of the four winners $2,500, along with an equal amount to their respective educational institutions. The competition aims to promote awareness of rare diseases and encourage diversity in K-12 classrooms. Winning lesson plans are available on sharemylesson.com. Sarepta's commitment to education comes alongside its leadership in precision genetic medicine, particularly in treating rare diseases.

Sarepta Therapeutics (NASDAQ:SRPT) announced on January 29, 2021, that it granted equity awards as an inducement for 26 new hires under its 2014 Employment Commencement Incentive Plan. The total options issued amounted to 20,565 shares, with an exercise price of $89.40, applying to the closing stock price on the grant date. Additionally, 7,760 restricted stock units (RSUs) were granted, which will vest over four years. This initiative aims to strengthen recruitment as Sarepta continues to lead in precision genetic medicine for rare diseases.

Sarepta Therapeutics and Genevant Sciences announced a collaboration to advance gene editing therapies for neuromuscular diseases. Under the agreement, Sarepta will have options for exclusive licenses to Genevant's lipid nanoparticle (LNP) delivery technology for four indications, including Duchenne muscular dystrophy. Genevant could receive $50 million in near-term payments and further milestone payments and royalties. The partnership aims to improve gene delivery using LNPs, enhancing the potential for effective treatments in genetic disorders.

Sarepta Therapeutics is set to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 10:00 a.m. E.T. The presentation will be followed by a Q&A session starting at 10:20 a.m. E.T. Interested parties can access the live webcast on Sarepta's investor relations page, where the session will also be archived for 90 days. Sarepta focuses on precision genetic medicine for rare diseases, with over 40 programs in development.